Emmes, a leading Clinical Research Organization (CRO) with a vision to advance public health and biopharmaceutical innovation, has taken a groundbreaking step with the acquisition of Essex Management. Essex is a prominent provider of bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is a major milestone for Emmes, allowing it to offer clients the most advanced solutions and expand its services. With the addition of Essex, Emmes will now be able to blaze new trails in clinical research and provide cutting-edge data strategies for biopharma clients.
The merger of Emmes and Essex will result in a clinical research powerhouse that’s at the forefront of innovation. With the combined power of Emmes’ advanced analytics solutions and Essex’s technology skills, the CRO will be better equipped to face global health challenges and lead the way in clinical research.
Essex’s reputation as a technology catalyst in the life sciences, combined with Emmes’ successful partnerships with the National Cancer Institute (NCI) and other public sector clients, will set the stage for a trailblazing partnership that will drive growth and bring new possibilities to life in the field of clinical research.
